CSIMarket
 
Cerus Corporation  (CERS)
Other Ticker:  
 
 
Price: $1.6800 $-0.01 -0.592%
Day's High: $1.79 Week Perf: 2.44 %
Day's Low: $ 1.66 30 Day Perf: -14.72 %
Volume (M): 781 52 Wk High: $ 3.08
Volume (M$): $ 1,313 52 Wk Avg: $1.97
Open: $1.66 52 Wk Low: $1.21



 Market Capitalization (Millions $) 304
 Shares Outstanding (Millions) 181
 Employees 309
 Revenues (TTM) (Millions $) 215
 Net Income (TTM) (Millions $) -50
 Cash Flow (TTM) (Millions $) -12
 Capital Exp. (TTM) (Millions $) 6

Cerus Corporation
Cerus Corporation is a biopharmaceutical company that has been dedicated to providing solutions for the enhancement of blood safety throughout the world since 1991. Their headquarters are located in Concord, California, and the company has additional facilities in France, Germany, and Switzerland.

Cerus Corporation focuses on the development of innovative technologies that can help prevent the transmission of diseases through blood transfusions. Their primary product is the INTERCEPT Blood System, which provides a broad-spectrum solution for the reduction of pathogens present in donated blood. It is a unique and proprietary technology that works by incorporating an FDA-approved chemical compound, known as amotosalen, to inactivate viruses, bacteria, and parasites in blood products.

The INTERCEPT Blood System targets the transfusion needs of individual patients by customizing blood components to meet their specific needs. This technology can also reduce the risk of transfusion-transmitted infections, such as dengue, Zika, chikungunya, and malaria. As such, it is becoming increasingly adopted in countries around the world, especially those with a high risk of disease transmission through transfusions.

Cerus Corporation's products and technologies have been approved by several regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company collaborates with several Worldwide Health Organisations, blood centers, and hospitals around the world. The INTERCEPT Blood System is used by over 150 centers in 30 countries, with over 5 million INTERCEPT-treated platelet and plasma units in circulation.

The company's management team comprises experts with vast experience in the health sector, which includes the commercialization of innovative blood products, and the successful registration of new pharmaceutical and medical device products globally.

Cerus Corporation is committed to continuously providing innovative products and services to meet necessary patient needs. With a commitment to excellence in research, development, and regulatory clinical trial programs, Cerus Corporation is at the forefront of reducing the risk of blood-borne diseases and ensuring patient safety in transfusion therapies.


   Company Address: 1220 Concord Avenue Concord 94520 CA
   Company Phone Number: 288-6000   Stock Exchange / Ticker: NASDAQ CERS
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Cerus Corporation

Cerus Corporation Shows Positive Earnings and Loss Improvements in Q3 2023, but Revenue Declines Pose Challenges



Cerus Corporation, a prominent player in the Medical Equipment & Supplies sector, recently released its financial results for the July to September 30, 2023, period. The company showcased improvements in both its earnings per share (EPS) and loss per share (LPS), indicating a step in the right direction. However, their revenue figures experienced a significant decline when compared to the previous year's Q3. Let's delve deeper into the financial highlights and put them into context.
EPS and LPS Performance:
The Q3 2023 financial report demonstrated a noteworthy decrease in LPS, where the company reported a loss of $-0.04 per share, compared to $-0.05 in the same period of the previous year. Additionally, EPS improved from $-0.07 to an undisclosed positive amount, showing an encouraging trend for Cerus Corporation.

Stock Transactions

Transforming Healthcare: Bloodbuy and Cerus Corporation Join Forces to Deliver Innovative Pathogen-Reduced Cryoprecipitated Fibrinogen Complex on Digital Marketplace

Published Wed, Nov 1 2023 6:46 PM UTC

Bloodbuy Partners with Cerus Corporation to Provide Pathogen-Reduced Cryoprecipitated Fibrinogen Complex on Digital Marketplace
Dallas-based healthcare software and services company, Bloodbuy, has announced a groundbreaking agreement with Cerus Corporation (NASDAQ: CERS) to offer the innovative Pathogen Reduced Cryoprecipitated Fibrinogen Complex, also known as INTERCEPT...

Cerus Corporation

Cerus Corporation Faces Revenue Decline, Widening Diminishing Returns in Latest Fiscal Period



Cerus Corporation, a medical equipment and supplies company, has recently released its financial results for the most recent fiscal period. These results show a combination of positive and negative developments, including widening diminishing returns and improved earnings per share. However, the company experienced a significant decline in revenue compared to the prior year. It also faced challenges with net shortfalls and increasing inventories. This article will analyze these financial results and provide insights into their implications for Cerus Corporation.
1. Diminishing Returns:
Cerus Corporation's diminishing returns widened to $-0.07 per share in the most recent fiscal period, compared to $-0.05 per share a year prior. This indicates a deterioration in the company's profitability on a per-share basis. Although the improvement in earnings per share from $-0.09 in the prior reporting period is a positive sign, the widening diminishing returns raise concerns about the company's long-term financial health.

Cerus Corporation

Cerus Corporation Faces Financial Challenges in Q1 2023, but Promising Future Prospects Emerge

Despite the challenging financial situation faced by Cerus Corporation in the first quarter of 2023, there are several reasons to remain bullish on the company's future prospects.
Firstly, while the company did see an increase in the shortfall per share compared to the same period last year and the previous quarter, it's crucial to note that this was largely due to external factors outside of Cerus' control. The COVID-19 pandemic has had a significant impact on the healthcare industry as a whole, particularly in terms of demand for plasma products, which is Cerus' main line of business. As the pandemic eases and healthcare systems recover, it's likely that this demand will pick up once again, and Cerus will be well-positioned to capitalize on this trend.






 

Cerus's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com